These findings are noteworthy because second-line treatment options are very limited for patients whose cancers no longer respond to the initial treatment, and we think that this could potentially represent a new option for these patients,' says Ng.Shorter pathway to the clinicBrequinar has already been approved for use in patients as an immunosuppressant, and there has been some preclinical research showing that brequinar and other DHODH inhibitors may be effective for other types of cancers.' Next steps for the researchers include optimizing the therapeutic efficacy of DHODH inhibitors and combining them with other currently available treatment options for, such as chemotherapy and immunotherapy.
We're excited because our findings could provide a new way to help small cell lung cancer patients in the future,' says Li.
0 kommentar(er)
